PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor.
The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.
The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children\u2019s pain from early years to early adulthood.
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world\u2019s most prolific diseases.
The awardees for the second round of the University of Oxford\u2019s Enriching Engagement funding scheme have now been announced, including a project from Paediatrics.
In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Oligonucleotides - short DNA or RNA molecules - have great therapeutic application for a range of diseases. Yet, their potential has not been fully unleashed because of challenges linked to efficient delivery. Read more to find out about recent developments in oligonucleotide modifications, and the platforms that may be used to deliver them to target sites.
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
The Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to \"The Adventures of Alice in Typhoidland\" co-created by the Oxford Vaccine Group.
The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including Professor Matthew Wood from the Department of Paediatrics.
![\"Necrotic](\"https://www.paediatrics.ox.ac.uk/news/university-spinout-pepgen-awarded-major-financing-to-target-duchenne-muscular-dystrophy-1/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n